Omicron Variant Escapes Therapeutic Monoclonal Antibodies (mAbs) Including Recently Released Evusheld®, Contrary to 8 Prior Main Variant of Concern (VOC)

Life Sciences [q-bio] Microbiology and Parasitology Bacteriology Life Sciences [q-bio] Microbiology and Parasitology Virology Life Sciences [q-bio] Microbiology and Parasitology Parasitology Life Sciences [q-bio] Human health and pathology Cardiology and cardiovascular system Life Sciences [q-bio] Human health and pathology Emerging diseases Life Sciences [q-bio] Human health and pathology Infectious diseases

Isabelle COMBE : Connect in order to contact the contributor

https://hal-amu.archives-ouvertes.fr/hal-03683548

Submitted on : Tuesday, May 31, 2022-4:51:21 PM

Last modification on : Wednesday, February 8, 2023-5:11:24 PM

Dates and versions

hal-03683548 , version 1 (31-05-2022)

Identifiers

HAL Id : hal-03683548 , version 1
DOI : 10.1093/cid/ciac143

Cite

Céline Boschi, Philippe Colson, Audrey Bancod, Valérie Moal, Bernard La Scola. Omicron Variant Escapes Therapeutic Monoclonal Antibodies (mAbs) Including Recently Released Evusheld®, Contrary to 8 Prior Main Variant of Concern (VOC). Clinical Infectious Diseases, 2022, ⟨10.1093/cid/ciac143⟩. ⟨hal-03683548⟩

Export

BibTeX TEI Dublin Core DC Terms EndNote Datacite

Collections

CNRS UNIV-AMU

6 View

0 Download